Indian pharma market grew 10.2% yoy in January 2026

Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise

Lyell Immunopharma launches groundbreaking Phase 3 CAR T-Cell trial for aggressive lymphoma

PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma

Torrent Pharmaceuticals posts Rs. 577 Cr Q3 profit; nine-month earnings jump to Rs. 1,725 Cr

DFE Pharma launches EcoLact 2030 to deliver verified CO2 cuts across pharma supply chains

The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio

Aurobindo Pharma reports strong Q3 FY26 performance, boosted by Europe & ARV growth

SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track

The company’s EBITDA margin remained resilient above 20%

Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder

LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution

Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets

Strides Pharma Inc receives USFDA closure report for Chestnut Ridge formulations facility

Inspection included drug device combinations covering our recent filing in nasal sprays domain

Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy

N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway